biologics

Biosimilars can save billions of healthcare dollarsAnalysis from RAND helps frame the potential of biosimilars to reduce spending on biologics.
In atopic dermatitis, are you employing the therapeutic ladder approach?Treatment for atopic dermatitis isn’t always straightforward. In this article, a physician outlines treatment approaches.
Atopic dermatitis: Biologics to watch in 2018In this article, we take a look at the development of new treatments for atopic dermatitis.
Two Companies Announce Drug RecallsTwo companies have issued recalls on their products.
European Commission approves adalimumab for paediatric uveitisThe European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.
Avelumab safety profile is “acceptable”Immunotherapy improves Merkel cell carcinoma, but questions remain.
Guselkumab front and center at EADV Congress
Guselkumab front and center at EADV CongressIL-23 inhibitors represent one more very effective strategy for controlling psoriasis with PASI rates comparable to other biologics.
Oral specialty drug options on the horizon
Oral specialty drug options on the horizonAs more specialty drugs are approved, cost control strategies are key.
Biologic risk tolerance differs for pregnant patientsOf several biologic agents that women of reproductive age can choose from to treat and manage psoriasis, not all have the same safety profile during pregnancy and lactation periods.
July Clinical ConsiderationsIn this month's Clinical Considerations, we take a look at biologics and treatments for seborrheic keratoses.